During the interview, which can be accessed free at http://www.wallstreetreporter.com , Mr. Gabriel discussed the future of pharmacogenomics and DNAPrint's recent licensing agreement with the Harvard Medical School's Beth Israel Deaconess Medical Center (BIDC) to clinically develop and commercially implement a new, super-potent form of erythropoietin (EPO), an anemia treatment drug.

"We believe that the recent FDA pronouncements about pharmacogenomics and the importance of understanding genetic ancestry of patients in combination with drug treatments is the wave of the future," Mr. Gabriel stated. "In fact, we see all drugs, or let's say a good majority of those drugs 10, 15, 20 years from now, and this is just my personal opinion, will have what we would call a diagnostic test tied directly to the administration of the drug so everyone knows that it is being personalized medically."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

     Company Contact:
     Richard Gabriel
     President and CEO
     941-366-3400
          -or-
     Ron Stabiner
     The Wall Street Group, Inc.
     212-888-4848